Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Diversified Services industry as a whole closed the day down 1.0% versus the S&P 500, which was down 0.8%. Laggards within the Diversified Services industry included

Bioanalytical Systems

(

BASI

), down 4.0%,

SmartPros

(

SPRO

), down 6.1%,

PDI

(

PDII

), down 2.0%,

Command Security

(

MOC

), down 6.4% and

EnviroStar

(

EVI

), down 5.1%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today:

Command Security

(

MOC

) is one of the companies that pushed the Diversified Services industry lower today. Command Security was down $0.14 (6.4%) to $2.06 on heavy volume. Throughout the day, 56,410 shares of Command Security exchanged hands as compared to its average daily volume of 24,100 shares. The stock ranged in price between $2.00-$2.16 after having opened the day at $2.16 as compared to the previous trading day's close of $2.20.

Command Security Corporation provides uniformed security officers and aviation security services to commercial, financial, industrial, aviation, and governmental customers in the United States. The company operates through Security and Aviation Safeguards divisions. Command Security has a market cap of $20.9 million and is part of the technology sector. Shares are up 6.8% year-to-date as of the close of trading on Friday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates

Command Security

as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the company's profit margins have been poor overall.

Highlights from TheStreet Ratings analysis on MOC go as follows:

  • This stock has managed to rise its share value by 47.97% over the past twelve months. Although MOC had significant growth over the past year, our hold rating indicates that we do not recommend additional investment in this stock at the current time.
  • COMMAND SECURITY CORP has shown improvement in its earnings for its most recently reported quarter when compared with the same quarter a year earlier. The company has demonstrated a pattern of positive earnings per share growth over the past two years. During the past fiscal year, COMMAND SECURITY CORP increased its bottom line by earning $0.12 versus $0.04 in the prior year.
  • MOC, with its decline in revenue, slightly underperformed the industry average of 4.1%. Since the same quarter one year prior, revenues slightly dropped by 0.9%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. When compared to other companies in the Commercial Services & Supplies industry and the overall market, COMMAND SECURITY CORP's return on equity is below that of both the industry average and the S&P 500.
  • The gross profit margin for COMMAND SECURITY CORP is currently extremely low, coming in at 14.71%. Regardless of MOC's low profit margin, it has managed to increase from the same period last year. Despite the mixed results of the gross profit margin, MOC's net profit margin of 1.83% is significantly lower than the industry average.

TST Recommends

You can view the full analysis from the report here:

Command Security Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close,

PDI

(

PDII

) was down $0.05 (2.0%) to $2.45 on heavy volume. Throughout the day, 42,409 shares of PDI exchanged hands as compared to its average daily volume of 18,400 shares. The stock ranged in price between $2.44-$2.50 after having opened the day at $2.46 as compared to the previous trading day's close of $2.50.

PDI, Inc. provides outsourced commercial services to pharmaceutical, biotechnology, and healthcare companies in the United States. PDI has a market cap of $38.3 million and is part of the technology sector. Shares are down 48.0% year-to-date as of the close of trading on Friday. Currently there is 1 analyst who rates PDI a buy, no analysts rate it a sell, and 1 rates it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates

PDI

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, poor profit margins, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.

Highlights from TheStreet Ratings analysis on PDII go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Providers & Services industry. The net income has significantly decreased by 200.7% when compared to the same quarter one year ago, falling from -$0.88 million to -$2.66 million.
  • The gross profit margin for PDI INC is rather low; currently it is at 16.38%. It has decreased from the same quarter the previous year. Along with this, the net profit margin of -8.41% is significantly below that of the industry average.
  • Net operating cash flow has declined marginally to -$1.83 million or 1.61% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 48.02%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 183.33% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • PDI INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, PDI INC continued to lose money by earning -$0.31 versus -$1.75 in the prior year. For the next year, the market is expecting a contraction of 111.3% in earnings (-$0.66 versus -$0.31).

You can view the full analysis from the report here:

PDI Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Bioanalytical Systems

(

BASI

) was another company that pushed the Diversified Services industry lower today. Bioanalytical Systems was down $0.10 (4.0%) to $2.40 on light volume. Throughout the day, 3,325 shares of Bioanalytical Systems exchanged hands as compared to its average daily volume of 11,200 shares. The stock ranged in price between $2.38-$2.52 after having opened the day at $2.52 as compared to the previous trading day's close of $2.50.

Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in North America, the Pacific Rim, Europe, and internationally. Bioanalytical Systems has a market cap of $18.4 million and is part of the technology sector. Shares are down 7.7% year-to-date as of the close of trading on Friday.

TheStreet Ratings rates

Bioanalytical Systems

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and weak operating cash flow.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on BASI go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Life Sciences Tools & Services industry. The net income has significantly decreased by 62.7% when compared to the same quarter one year ago, falling from $0.58 million to $0.22 million.
  • Net operating cash flow has significantly decreased to $0.21 million or 75.43% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Life Sciences Tools & Services industry and the overall market, BIOANALYTICAL SYSTEMS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • BIOANALYTICAL SYSTEMS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past 2 years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, BIOANALYTICAL SYSTEMS INC turned its bottom line around by earning $0.09 versus -$0.87 in the prior year.
  • 39.46% is the gross profit margin for BIOANALYTICAL SYSTEMS INC which we consider to be strong. Regardless of BASI's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, the net profit margin of 3.56% trails the industry average.

You can view the full analysis from the report here:

Bioanalytical Systems Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.